What Happened
Douglas Daniel Files, D.O., of Levittown, Pennsylvania, agreed in May 2023 to pay $100,000 to resolve allegations that he violated the Controlled Substances Act. The government alleged that he failed to maintain complete records of testosterone, a Schedule IIIN controlled substance, failed to keep receipt and dispensing records, failed to perform biennial inventories and wrote prescriptions for stock. DEA investigators discovered these issues in April 2022. As part of the settlement he entered a three-year Memorandum of Agreement with the DEA imposing additional controlled-substance handling obligations. There was no determination of liability.
“has agreed to pay $100,000 to resolve allegations that he violated the Controlled Substances Act”
Related Guidance
- 15 Red Flags of Drug Diversion — Behavioral and transactional indicators of diversion.
- Investigation Playbook — How to investigate suspected diversion inside an organization.